RSV, or respiratory syncytial virus, can hit adults hard. Though it usually feels like a cold, with symptoms clearing up within a couple weeks, the virus can lead to more serious lung infections in ...
Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...
"This study includes CDC’s first comprehensive estimates of RSV disease burden in U.S. adults, including hospitalizations and in-hospital deaths. It demonstrates that RSV caused a substantial burden ...
Clinicians underutilize RSV testing in adults with respiratory or cardiac exacerbations, potentially obscuring the true burden of disease.
Hosted on MSN
Q&A: RSV's hidden toll—adults of all ages may struggle with breathlessness, daily activities for months
Recovering from respiratory syncytial virus often doesn't end when it's time to leave the hospital, even for younger adults. Subscribe to our newsletter for the latest sci-tech news updates. For ...
Respiratory syncytial virus (RSV) vaccines were an estimated 79% effective against dangerous virus-related blood clots among ...
Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to ...
"Our findings highlight how multimorbidity is associated with more severe RSV outcomes, and support RSV vaccination for eligible high-risk patients with multiple underlying conditions." — Kevin Ma, ...
ST. PETERSBURG, Fla. — While the respiratory syncytial virus, known as RSV, is often thought of as a childhood issue, experts said many overlook its impact on adults. As a result, the Centers for ...
After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...
Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse ...
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results